X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition advances Coherus' immuno-oncology pipeline by adding two clinical stage assets, SRF388 (casdozokitug), a novel IL-27-targeted antibody being evaluated in Phase 2 in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody for advanced solid tumors.
Lead Product(s): Casdozokitug,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: $66.9 million Upfront Cash: $26.9 million
Deal Type: Acquisition September 08, 2023
Details:
The acquisition advances Coherus' immuno-oncology pipeline by adding two clinical stage assets, SRF388, a novel IL-27-targeted antibody being evaluated in Phase 2 trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody for advanced solid tumors.
Lead Product(s): SRF388,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: $65.0 million Upfront Cash: $25.0 million
Deal Type: Acquisition June 16, 2023
Details:
SRF114 is a fully human, afucosylated anti-CCR8 antibody, which depletes CCR8+ Treg cells within the tumor microenvironment by inducing antibody-dependent cellular cytotoxicity or antibody-dependent cellular phagocytosis pathways.
Lead Product(s): SRF114
Therapeutic Area: Oncology Product Name: SRF114
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
SRF388, a fully human anti-IL-27 antibody designed to inhibit the activity of immunosuppressive cytokine and preclinical studies have shown that SRF388 blocks the immunosuppressive effect of IL-27, resulting in immune cell activation in combination with other cancer therapies.
Lead Product(s): SRF388,Pembrolizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface has initiated a single-arm Phase 2 study evaluating SRF388 in combination with pembrolizumab in patients with NSCLC.
Lead Product(s): SRF388,Pembrolizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine, targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks immunosuppressive biologic effects of IL-27.
Lead Product(s): SRF388
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: VIB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Loss of IL-27 function, through either genetic deficiency or pharmacologic inhibition by SRF388, a first-in-class anti-IL-27 mAB, leads to tumor growth inhibition in mouse models and clinical data have shown monotherapy activity of SRF388 in patients with cancer.
Lead Product(s): SRF388,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Researchers found that IL-27 receptor signaling promoted for SRF388 in HCC development in mice, and that IL-27 served as an immunological checkpoint that regulates natural killer (NK) cell and innate immune cell activation.
Lead Product(s): SRF388,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2022
Details:
SRF388 targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with cancer therapies including anti-PD-1 therapy.
Lead Product(s): SRF388,Pembrolizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
SRF388, a fully human anti-IL-27 antibody designed to inhibit activity of immunosuppressive cytokine, also targets rate-limiting p28 subunit, preclinical studies showed treatment blocks immunosuppressive biologic effects of IL-27 resulting in immune cell activation.
Lead Product(s): SRF388,Pembrolizumab
Therapeutic Area: Oncology Product Name: SRF388
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
